Oncology Drug Costs Can Be ‘Financial Toxicity,’ ASCO Told
This article was originally published in The Pink Sheet Daily
Executive Summary
Memorial Sloan Kettering’s Saltz challenges oncology drug prices and urges a broader focus on value in a high-profile address to the ASCO annual meeting.
You may also be interested in...
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.